Sarepta Therapeutics, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -15.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.34 | $0.42 | +23.5% | Beat | |
| Q1 FY26 | not reported | $3.09 | not reported | not reported | |
| Q4 FY25 | not reported | $-3.87 | not reported | not reported | |
| Q3 FY25 | $-0.37 | $-0.28 | +24.3% | Beat | |
| Q2 FY25 | $0.78 | $1.70 | +118.0% | Beat | |
| Q1 FY25 | not reported | $-3.84 | not reported | not reported | |
| Q4 FY24 | $1.87 | $1.50 | -19.8% | Miss | |
| Q3 FY24 | not reported | $0.24 | not reported | not reported | |
| Q2 FY24 | $0.00 | $0.07 | not reported | Beat | |
| Q1 FY24 | not reported | $0.38 | not reported | not reported | |
| Q4 FY23 | not reported | $0.47 | not reported | not reported | |
| Q3 FY23 | not reported | $-0.46 | not reported | not reported |
Back to SRPT overview · SRPT holders · SRPT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.